SINGAPORE, Nov. 11, 2026 /PRNewswire/ — Novo Tellus has received enquiries following our recent reduction in shareholding in ISDN Holdings Limited (SGX: I07; HKEX: 1656), as disclosed in our substantial shareholder notifications filed with the SGX and HKEX in the last two months.
Novo Tellus invests in companies with strong fundamentals, good leadership, and long-term growth opportunities in attractive markets. We work with companies with the aim of clarifying strategy, supporting business focus, and building sustainable growth.
We are proud of our partnership with ISDN and the ongoing accomplishments of ISDN’s Managing Director and President, Mr Teo Cher Koon (CK Teo), and his team. In ISDN’s interim results announcement dated 14 August 2026, Mr. Teo highlighted the broad-based demand ISDN is seeing across diversified growth and long-term prospects, as well as ISDN’s momentum in expanding markets and capitalising on long-term automation demand.
In its 1H2026 results, ISDN also noted that its “order book has more than doubled from a year ago”, and that “favourable industry tailwinds continue to support the Group’s long-term business growth in industrial automation and renewable energy businesses”.
Novo Tellus’ decision to sell shares was driven by fund management considerations, and does not reflect a change in its views of ISDN, its markets, or its management team.
Nothing in this statement is a recommendation to buy, sell or hold ISDN shares. Novo Tellus may trade in ISDN’s shares from time to time in the ordinary course as part of fund management. Shareholders and potential investors are advised to exercise caution when dealing in ISDN shares, and should consult stockbrokers, bank managers and other professional advisers in case of doubt.
ข่าวที่เกี่ยวข้อง
- Xinhua Silk Road: Jing’an District promotes investment opportunities, global business cooperation at 2026 CIIE
- Binance Blockchain Week Bangkok 2026 Unveils First Wave of Speakers, Spotlighting the Convergence of Traditional Finance and Digital Assets
- Ascletis Submits IND Application to the U.S. FDA for ASC30_39 FDC, a Potentially First-in-Class Oral Small Molecule Fixed-Dose Combination of GLP-1R Agonist and Selective Amylin Receptor Agonist, for the Treatment of Obesity
- Ali Y. Koç: ‘The Energy Transition Has Become the Cornerstone of Competitiveness in Industry’
